文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

冬凌草甲素增溶和生物利用度提高的研究进展：综述

Solubility and Bioavailability Enhancement of Oridonin: A Review.

机构信息

College of pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.

出版信息

Molecules. 2020 Jan 14;25(2):332. doi: 10.3390/molecules25020332.

DOI:10.3390/molecules25020332
PMID:31947574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7024198/
Abstract

Oridonin (ORI), an ent-kaurene tetracyclic diterpenoid compound, is isolated from Chinese herb with various biological and pharmacological activities including anti-tumor, anti-microbial and anti-inflammatory effects. However, the clinical application of ORI is limited due to its low solubility and poor bioavailability. In order to overcome these shortcomings, many strategies have been explored such as structural modification, new dosage form, etc. This review provides a detailed discussion on the research progress to increase the solubility and bioavailability of ORI.

摘要

冬凌草甲素（ORI）是一种来自中国草药的贝壳杉烷四环二萜类化合物，具有多种生物和药理活性，包括抗肿瘤、抗菌和抗炎作用。然而，由于其溶解度低和生物利用度差，ORI 的临床应用受到限制。为了克服这些缺点，已经探索了许多策略，如结构修饰、新剂型等。本文详细讨论了提高 ORI 溶解度和生物利用度的研究进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/d510ba658538/molecules-25-00332-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/91c79cb0feb8/molecules-25-00332-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/5c52aeaf7239/molecules-25-00332-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/cc8e392be304/molecules-25-00332-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/94822fa9c910/molecules-25-00332-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/a08b394f36fc/molecules-25-00332-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/51606f6c488f/molecules-25-00332-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/1dc83deee03d/molecules-25-00332-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/0d0df7562798/molecules-25-00332-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/d510ba658538/molecules-25-00332-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/91c79cb0feb8/molecules-25-00332-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/5c52aeaf7239/molecules-25-00332-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/cc8e392be304/molecules-25-00332-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/94822fa9c910/molecules-25-00332-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/a08b394f36fc/molecules-25-00332-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/51606f6c488f/molecules-25-00332-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/1dc83deee03d/molecules-25-00332-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/0d0df7562798/molecules-25-00332-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f653/7024198/d510ba658538/molecules-25-00332-g009.jpg

相似文献

[1]
Solubility and Bioavailability Enhancement of Oridonin: A Review.

Molecules. 2020-1-14

[2]
Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption.

Int J Pharm. 2015-2-20

[3]
Molecular Insight in the Multifunctional Effects of Oridonin.

Drugs R D. 2015-9

[4]
Preparation and evaluation of self-microemulsifying drug delivery system of oridonin.

Int J Pharm. 2008-5-1

[5]
Preparation, Characterization, and Evaluation of Liposomes Containing Oridonin from .

Molecules. 2022-1-27

[6]
Recent Development of Oridonin Derivatives with Diverse Pharmacological Activities.

Mini Rev Med Chem. 2019

[7]
Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound.

Int J Mol Sci. 2016-8-24

[8]
Oridonin, a promising antitumor natural product in the chemotherapy of hematological malignancies.

Curr Pharm Biotechnol. 2014

[9]
Research Progress and Future Development Potential of Oridonin in Pharmacological Activities.

Curr Mol Pharmacol. 2023

[10]
Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens.

Biochem Biophys Res Commun. 2005-11-11

引用本文的文献

[1]
Research progress and molecular mechanism of oridonin in the treatment of malignant melanoma.

Front Oncol. 2025-6-17

[2]
Rutaecarpine alleviates hepatic ischemia‒reperfusion injury in liver transplantation by inhibiting inflammatory response and oxidative stress.

Front Pharmacol. 2025-2-3

[3]
Enhancing cancer therapy: advanced nanovehicle delivery systems for oridonin.

Front Pharmacol. 2024-12-3

[4]
Synthesis and Application of a pH-Responsive Functional Metal-Organic Framework: In Vitro Investigation for Delivery of Oridonin in Cancer Therapy.

Molecules. 2024-6-4

[5]
Glutathione-depleting Liposome Adjuvant for Augmenting the Efficacy of a Glutathione Covalent Inhibitor Oridonin for Acute Myeloid Leukemia Therapy.

J Nanobiotechnology. 2024-5-30

[6]
Integrating Epigenetics, Proteomics, and Metabolomics to Reveal the Involvement of Wnt/β-Catenin Signaling Pathway in Oridonin-Induced Reproductive Toxicity.

Toxics. 2024-5-7

[7]
Research and Development Progression of Oridonin for Hematological Malignancies Therapy.

Curr Med Chem. 2025

[8]
Angelica Sinensis Polysaccharide-Based Nanoparticles for Liver-Targeted Delivery of Oridonin.

Molecules. 2024-2-5

[9]
Nanotechnology-Based Strategies in Parasitic Disease Management: From Prevention to Diagnosis and Treatment.

ACS Omega. 2023-11-1

[10]
The Natural Product Oridonin as an Anticancer Agent: Current Achievements and Problems.

Curr Pharm Biotechnol. 2024

本文引用的文献

[1]
Docetaxel-loaded PEO-PPO-PCL/TPGS mixed micelles for overcoming multidrug resistance and enhancing antitumor efficacy.

J Mater Chem B. 2015-5-28

[2]
Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier.

Molecules. 2019-9-16

[3]
Delivery of Oridonin and Methotrexate via PEGylated Graphene Oxide.

ACS Appl Mater Interfaces. 2019-6-21

[4]
Micro/Nanoparticle Delivery Systems for Ocular Diseases.

Assay Drug Dev Technol. 2019

[5]
ROS/JNK/c-Jun axis is involved in oridonin-induced caspase-dependent apoptosis in human colorectal cancer cells.

Biochem Biophys Res Commun. 2019-4-10

[6]
A validated UPLC-MS/MS method to determine free and total irinotecan and its two metabolites in human plasma after intravenous administration of irinotecan hydrochloride liposome injection.

J Pharm Biomed Anal. 2019-3-18

[7]
Metabolic profile of lung-targeted docetaxel liposomes in rabbits, rats and mice.

Xenobiotica. 2020-2

[8]
CD44 Assists the Topical Anti-Psoriatic Efficacy of Curcumin-Loaded Hyaluronan-Modified Ethosomes: A New Strategy for Clustering Drug in Inflammatory Skin.

Theranostics. 2019-1-1

[9]
Oridonin enhances the radiosensitivity of lung cancer cells by upregulating Bax and downregulating Bcl-2.

Exp Ther Med. 2018-12

[10]
Antifibrosis Effect of Novel Oridonin Analog CYD0618 Via Suppression of the NF-κB Pathway.

J Surg Res. 2018-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索